Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference
June 30, 2010
Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference
"Myriad is very much a player in the field of companion diagnostics," Myriad Genetics CEO Peter Meldrum told investors at the Goldman Sachs annual global healthcare conference earlier this month.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Missed Opportunity: Would PGx Have Helped Sanofi-Aventis Avoid Phase III Failure for Iniparib?
February 2, 2011 / Pharmacogenomics Reporter - Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes
June 15, 2011 / Pharmacogenomics Reporter - MDxHealth Nets Methylation Biomarker Deal with Pfizer, Partners for PARP Inhibitor
February 2, 2011 / Pharmacogenomics Reporter - Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter